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Abstract
Background: Numerous studies from different labs around the world report human cardiac progenitor cells (hCPCs) as
having a role in myocardial repair upon ischemia/reperfusion (I/R) injury, mainly through auto/paracrine signaling. Even
though these cell populations are already being investigated in cell transplantation-based clinical trials, the
mechanisms underlying their response are still poorly understood.
Methods: To further investigate hCPC regenerative process, we established the first in vitro human heterotypic model
of myocardial I/R injury using hCPCs and human-induced pluripotent cell-derived cardiomyocytes (hiPSC-CMs). The co-
culture model was established using transwell inserts and evaluated in both ischemia and reperfusion phases regarding
secretion of key cytokines, hiPSC-CM viability, and hCPC proliferation. hCPC proteome in response to I/R was further
characterized using advanced liquid chromatography mass spectrometry tools.
Results: This model recapitulates hallmarks of I/R, namely hiPSC-CM death upon insult, protective effect of hCPCs on
hiPSC-CM viability (37.6% higher vs hiPSC-CM mono-culture), and hCPC proliferation (approximately threefold increase
vs hCPCs mono-culture), emphasizing the importance of paracrine communication between these two populations. In
particular, in co-culture supernatant upon injury, we report higher angiogenic functionality as well as a significant
increase in the CXCL6 secretion rate, suggesting an important role of this chemokine in myocardial regeneration. hCPC
whole proteome analysis allowed us to propose new pathways in the hCPC-mediated regenerative process, including
cell cycle regulation, proliferation through EGF signaling, and reactive oxygen species detoxification.
Conclusion: This work contributes with new insights into hCPC biology in response to I/R, and the model established
constitutes an important tool to study the molecular mechanisms involved in the myocardial regenerative process.
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Background
Acute myocardial infarction (AMI) is still a major cause
of death in the world [1]. AMI consists on the cessation
of blood flow, causing oxygen and nutrient supply im-
balance, leading to myocardial tissue damage, with loss
of cardiomyocytes (CMs). For AMI patients, the inter-
vention of choice is immediate myocardial reperfusion
with restoration of blood flow. However, this process
can aggravate the damage, as the increase of molecular
oxygen levels occurs at a toxic rate (ischemia-reperfu-
sion (I/R) injury), contributing to up to 50% of the final
scar tissue size [2]. Current treatments are successful in
reducing immediate mortality but do not avoid the sub-
sequent scarring and degeneration of myocardium tissue
with loss of contractile function, often leading to chronic
heart failure (CHF), a highly fatal condition in which the
only available clinic option is heart transplant [3].
Regenerative medicine-based strategies for infarcted
myocardium include autologous and allogeneic cell ther-
apies. Several cell types were already applied in clinical
trials, including bone marrow-derived mesenchymal
stromal cells (e.g., REPAIR-ACS- NCT00711542, BOOST-
NCT00224536), adipose tissue-derived mesenchymal
stromal cells (e.g., ADVANCE- NCT01216995, and
APOLLO- NCT00442806), and cardiac progenitor cells
(CPCs) (e.g., SCIPIO- NCT00474461, CADUCEUS -
NCT00893360, and CAREMI- NCT02439398). For all cell
types, clinical trials have demonstrated some physiological
improvements but very low cell retention after some
weeks, suggesting that the overall beneficial effect of
transplanted cells is due to paracrine modulation rather
than differentiation and functional integration in the tissue
[4]. In fact, novel strategies that focused on the induction
of the endogenous heart regenerative potential, such as
direct growth factor administration, have shown to induce
tissue regeneration by reduction of fibrosis, induction of
angiogenesis, inhibition of apoptotic processes, and re-
cruitment of endogenous CPCs [5, 6].
Although in low percentages, endogenous CPCs seem
to play an important regenerative role in cardiac homeo-
stasis and in response to physiological stress and I/R in-
jury. While the physiological alterations undergone by
CMs during I/R have been extensively covered, the
mechanisms by which CPCs exert their protective role
are still not well defined. Upon injury, there are in-
creased levels of signaling growth factors and cytokines
released in the myocardium [7, 8]. Such signals have
already been proposed to trigger CPC proliferation, dif-
ferentiation, migration to the site of injury, and growth
factor secretion that together have an effect on cardio-
myocyte protection, reduction of inflammation, and re-
duction of scar tissue size, which has already been
documented in several animal studies [9, 10]. Neverthe-
less, some doubts and controversy still exist regarding
the identity and ability of CPCs to generate new CMs
upon injury [11, 12]. Such concerns have recently been
enhanced with the retraction of several CPC studies
from Piero Anversa’s lab [13]. The hCPCs employed in
this work are not the same population involved in this
controversy and were isolated and cultured using a dif-
ferent protocol (Patent WO2014141220A1), which was
also used for the isolation of the hCPC population re-
cently evaluated for the allogeneic treatment of AMI in
CAREMI clinical trial (NCT02439398). Importantly,
these cells were already extensively characterized at the
immunomodulatory [14–17], total proteome [18], mem-
brane proteome [19, 20], and secretome [21] levels. The
regenerative benefit of these cells was studied in vivo in
pig AMI animal model [22, 23].
Mainly due to the lack of relevant human models, the
role of CPCs in I/R injury has been studied in vitro with
murine cells. There are relevant gaps between murine
and human cardiac physiology both in vitro and in vivo,
such as different functionality of CM ion channels and a
higher tolerability to drugs in mice and mice cells. Such
differences can cause misinterpretation of the results
and have already been pointed as one of the causes of
high drug attrition rates [24].
Aiming at filling the gap between murine and human
in vitro models, in this work we have established the first
in vitro human cell-based myocardial I/R injury model,
using human CPCs (hCPCs) and human-induced pluri-
potent stem cell-derived CMs (hiPSC-CMs). The goal of
our work is to use this co-culture model as a tool to bet-
ter understand and characterize hCPC response to I/R
injury, and its effect on CM death and survival upon in-
jury. Our model was able to recapitulate important fea-
tures of AMI, namely CM death, a paracrine protective
effect of CPCs in CM survival, and CPC proliferation ac-
tivation. For the first time, CXCL6, a cytokine with doc-
umented angiogenic properties, already identified as
having an important regenerative role in both mesen-
teric and myocardial infarction was found to be highly
secreted by hCPCs upon I/R injury in the co-culture
condition. Moreover, we also demonstrated higher an-
giogenic potential of the co-culture supernatant upon is-
chemia. Human CPC whole proteome analysis showed
that upon injury, and in the presence of hiPSC-CMs,
there was an enrichment in proteins involved in path-
ways and functions related with cell proliferation, para-
crine signaling, stress response, and regeneration




CPCs were obtained from human right atria appendage
myocardial tissue, isolated, and characterized as described
Sebastião et al. Stem Cell Research & Therapy           (2019) 10:77 Page 2 of 16
elsewhere [14]. Cells were cultured at 37 °C in humidified
incubators (5% CO2, 3% O2) in expansion medium
(ExpM) composed by DMEM:F12: Neurobasal medium
(1:1), supplemented with 1% penicillin streptomycin, 10%
fetal bovine serum embryonic stem cell-qualified, N2 sup-
plement (1×), B27 supplement (1× ), 0.9 mM l-glutamine,
50 μM β-mercaptoethanol (Sigma), insulin transferrin sel-
enium (0.5× ), 10 ng/mL bFGF, 20 ng/mL EGF-I, and 30
ng/mL IGF-II (Prepotech) (all percentages in v/v).
Medium was replaced by 50% every 3 days. Cells were
subcultured when about 80% confluent using Tryple™ Se-
lect Enzyme for 5min at 37 °C. All cell culture reagents
were purchased from Gibco, Life Technologies unless
otherwise stated.
Human iPSCs (DF19-9-11 T.H, WiCell) were cultured
and differentiated to CMs (hiPSC-CMs) as previously
described [25, 26]. Using this protocol, monolayer cul-
tures composed of > 90% of hiPSC-CMs were obtained
after 15 days. To further improve the maturation state of
this cell population, hiPSC-CMs were cultured for add-
itional 10 days in Pluricyte Medium (NCardia), as de-
scribed elsewhere [27]. Cells were maintained at 37 °C in
humidified incubators (5% CO2, 95% air).
Ischemia/reperfusion injury setup
I/R experiments were performed with the following:
mono-cultures of hCPCs (plated at 2 × 104 hCPCs/cm2),
mono-cultures of hiPSC-CMs (plated at 1–1.5 × 105
hiPSC-CMs/cm2), and co-cultures of the two cell types
(hCPCs:hiPSC-CMs 1:10–1:20) using Transwell® perme-
able insert supports (0.4 μm pore size, Corning). The in-
sert supports are semi-permeable polyester membranes
separating both cell types allowing paracrine interaction.
hCPCs were seeded in transwell supports (1.2 × 104
hCPCs/insert and positioned above hiPSC-CM culture
dishes (1.2–2.4 × 105 hiPSC-CMs/ well) at the begin-
ning of the ischemia phase, allowing a paracrine
interaction between the two cell types during all the se-
quence of I/R injury.
All cell populations were cultured in ExpM at 3% O2
(myocardial physiologic normoxia) in humidified incu-
bators (5% CO2, 95% air) at least 15 h before I/R experi-
ments. I/R injury experimental setup is illustrated in
Fig. 1. Briefly, ischemia was mimicked by replacing
ExpM by ischemic mimetic solution (IMS; in mM:
NaCl, 135; KCl, 8; MgCl2, 0.5; NaH2PO4, 0.33; HEPES,
5.0; CaCl2, 1.8; Na
+-lactate, 20; pH 6.8) [28] and by
placing cells in a N2 gaseous environment at 37 °C.
After 5 h of ischemia, reperfusion was mimicked by
re-establishing control culture conditions (ExpM at 3%
O2). Control cultures for all culture setups were main-
tained in parallel (ExpM at 3% O2). The impact of I/R
injury was evaluated regarding hCPC proliferation,
hiPSC-CM viability, secretion of growth factors, and
hCPC whole proteome analysis.
Total cell number
hCPC number was accessed by nuclei count with crystal
violet solution staining. Briefly, cells were resuspended
in lysis buffer (0.1% Triton X-100 in 0.1M citric acid)
directly in culture wells/transwells and incubated at 37 °
C for at least 48 h. Nuclei were stained with crystal violet
dye (0.1% v/v in lysis buffer) and the total number of
nuclei counted in a Fuchs-Rosenthal hemocytometer
chamber. Fold increase in hCPC number was calculated
as the ratio between the cell number at the experimental
time point assayed and cell number before I/R injury.
Cell viability
hiPSC-CM viability was assessed by cell membrane in-
tegrity analysis: cell monolayers were incubated with
20 μg/mL fluorescein diacetate (FDA), that stains viable
cells, and 10 μg/mL propidium iodide (PI), a membrane
impermeable DNA-dye that stains non-viable cells, in
DPBS for 2–5 min. Samples were then observed under a
fluorescence microscope (DMI 6000, Leica Microsys-
tems GmbH).
hiPSC-CM viability was further assessed using the
metabolic indicator PrestoBlue® Cell Viability Reagent
(Life Technologies), according to the manufacturer’s rec-
ommendation. Briefly, cells were incubated with ExpM
containing 10% (v/v) PrestoBlue®, for 1 h. Supernatant’s
fluorescence was measured in 96-well plates using a
microwell plate fluorescence reader (Infinite 200 PRO
NanoQuant TECAN). Values obtained were normalized
by the initial values obtained before I/R injury.
Immunofluorescence microscopy
Cell monolayers were washed with DPBS and fixed in
4% (w/v) paraformaldehyde (PFA) and 4% (w/v) sucrose
in DPBS for 20 min. Afterwards, cells were perme-
abilized for 10 min in 0.1% (v/v) Triton X-100 in DPBS
and blocked with 0.2% (v/v) fish skin gelatin (FSG) in
DPBS for 30 min, at room temperature (RT, 18–20 °C).
Cells were then incubated with primary antibodies di-
luted in 0.125% (v/v) FSG, 0.1% (v/v) Triton X-100 for 2
h at RT. Cells were washed with DPBS and incubated
with secondary antibodies diluted in 0.125% (v/v) FSG,
0.1% (v/v) Triton X-100 for 1 h at RT in the dark. The
following primary antibodies were used: α-sarcomeric
actinin (1:200, Sigma), CD26 (1:80, Thermo Fisher), and
Ki-67 (1:200, Abcam).
Flow cytometry
After a 5 min dissociation step with TrypLE™Select at 37
°C, cells were washed with DPBS by centrifugation and a
total of 2–3 × 105 cells were used per analysis. For
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membrane markers, cells were incubated with the pri-
mary antibody for 1 h and with the secondary antibody
for 30 min at 4 °C in DPBS with 5% (v/v) FBS. For intra-
cellular markers, cells were permeabilized using the In-
side Stain Kit (Miltenyi Biotec) according to the
manufacturer‘s instructions. The following primary anti-
bodies were used: SirPα/β (1:20, CD172a/b-PE, BioLe-
gend), Troponin T (1:200, TnT, Thermo Scientific),
CD105 (1:20,BD Pharmingen), CD166 (1:20,BD Phar-
mingen), CD44 (1:5, eBiosciences), CD11b (1:10, AbD-
Serotec), CD34 (1:5, BD Pharmingen), CD45 (1:5, BD
Pharmingen), and isotype controls mouse igG1k (1:5,
BD Pharmingen), mouse IgG1 (1:2.5,Santa Cruz Biotech-
nologies), and rat IgG2b (1:5, eBiosciences). Cells were
analyzed in a CyFlow® space (Partec GmbH) instrument,
registering at least 10,000 events/sample.
Quantification of growth factors
Quantification of growth factors CXCL6 and IGF-1 in
cell conditioned medium was performed by ELISA
Human Quantikine ELISA kit (R&D Systems), according
to the manufacturer’s instructions. Optical density was
measured in 96-well plates using a microwell plate
reader (Infinite 200 PRO NanoQuant TECAN). The
specific rate of growth factor secretion was estimated ac-
cording to the following equation: qGF ¼ ΔCG FCcellΔt
where ΔCGF (g/L) is the variation in growth factor
concentration during the time period Δt (h) and Ccell is
the concentration of cells (cell/L).
HUVEC culture and tube formation assay
Human umbilical vein endothelial cells (HUVECs, Lonza
ref. 2517A) were cultured at 37 °C in humidified incuba-
tors (5% CO2, 3% O2), in 0.1% gelatin-coated plates with
Endothelial Cell Growth medium 2 (ECGM2, PromoCell).
Medium was replaced every 3 days. Cells were subcultured
when about 90% confluent using 0.5% Trypsin-EDTA for
7min at 37 °C.
Tube formation assay was performed according to
Pedroso et al. [29]. Briefly, ice-cold undiluted Matrigel
(Growth factor Reduced, BD Biosciences) (1.97 mg/cm2)
was used to coat 96-well plates and incubated for 40 min
at 37 °C to allow the Matrigel to solidify. HUVECs were
seeded at a density of 5.5 × 104 cells/cm2 and incubated
with the conditioned media from I/R experiments.
ECGM2 was used as positive control for tube formation.
At least four independent images were acquired per
Fig. 1 Schematic representation of ischemia/reperfusion injury experimental setup. Ischemia was mimicked by replacing expansion medium by
ischemic mimetic solution (IMS) and by culturing cells in a N2 gaseous environment. After 5 h of ischemia, reperfusion was mimicked by re-
establishing normoxic culture conditions (ExpM at 3% O2). I/R setup was performed using mono-cultures of hiPSC-CMs, mono-cultures of hCPCs,
and co-cultures of the two cell types using transwell permeable inserts. The impact of the I/R was evaluated regarding hCPC proliferation, hiPSC-
CM viability, hCPC whole proteome, and secretion of IGF-1 and CXCL6 factors in different time points: (BI—before injury; Post I—post ischemia;
Post R—post reperfusion). Control cultures were done in parallel (using normoxic conditions)
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condition after 4 h of incubation and the morphological
aspects of the tube network were quantified using the
ImageJ angiogenesis analyzer plugin, including total
branching length (sum of length of the trees composed
from segments and branches), total segment length (sum
of length of the segments), and number of nodes [30].
All cell culture reagents were purchased from Gibco,
Life Technologies unless otherwise stated.
Whole proteome analysis
hCPCs were harvested and washed twice with DPBS by
centrifugation. Supernatants were discarded and cell
pellets were placed at − 80 °C until further analysis. Pro-
teins were extracted, quantified, and processed from cell
pellets as described elsewhere [31]. Two biological
replicates with three technical replicates per time point
were run. Protein samples were analyzed by NanoLC–
MS/MS using TripleTOF 6600 (ABSciex). External cali-
bration was performed using beta-galactosidase digest
(ABSciex). The 40 most intense precursor ions from the
MS spectra were selected for MS/MS analysis. Data were
acquired with the Analyst software TF 1.7 (ABSciex).
The raw MS and MS/MS data were analyzed using Pro-
tein Pilot Software v.5.0 (ABSciex) for protein identifica-
tion. The search was performed against the Swissprot
protein database with taxonomic restriction to Homo sa-
piens. Protein identification was considered when un-
used scores were greater than 1.3 (95% confidence).
Analysis of the protein lists was performed using Venny
2.1 (http://bioinfogp.cnb.csic.es/tools/venny/) and in-
genuity pathway analysis (IPA, Qiagen). Statistically
significant representation of biological functions and ca-
nonical pathways was identified based on IPA p value.
This probability score is calculated taking into account
the total number of proteins known to be associated
with a given function or pathway, and their representa-
tion in the experimental dataset. IPA’s calculated p value
is displayed as –log (p value). All proteomic data have
been deposited in the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) via the
PRIDE partner repository with the dataset identifier
PXD008156.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism6 (GraphPad Software Inc.). All data are shown as
mean with standard deviation. Differences in hCPC fold
increases (n = 3/5), differences in hiPSC-CM viability
percentages (n = 2/3), differences in specific growth rate
secretion of CXCL6 and IGF-1 (n = 3), and differences in
tube formation (n = 3/4) were analyzed by parametric
one-way ANOVA Tukey test. Individual p values for
each comparison were obtained using the multiplicity
adjusted p value test. Differences for ki67 expression
percentage were analyzed by parametric Student’s t test
with Welch’s correction. p values below 0.05 were con-
sidered significant.
Results
In this study, we developed an in vitro I/R injury
co-culture model with hCPCs and hiPSC-CMs, using
transwell inserts to allow paracrine communication be-
tween the two cell types.
Identity of hCPCs was demonstrated by the expression
of hCPC cell-surface-specific markers by flow cytometry.
As demonstrated before [18], this cell population is
negative for CD34, CD45, CD11b, and CM marker cTnT
and displays a high percentage of cells positive for adult
stem cell markers CD44 (97.2% ± 2.2), CD105 (95.5% ±
1.7), and CD166 (75.1% ± 13.3) (Additional file 1: Figure
S1A). The expression of CD26 (DPP4), recently found to
be selectively upregulated in hCPCs when compared to
human mesenchymal stem cells and human dermal
fibroblasts (Tóran J, López J, Gomes-Alves P, et al., sub-
mitted), was also detected by immunostaining (Add-
itional file 1: Figure S1B).
During the establishment of the I/R injury setup, two
different types of hiPSC-CMs were tested: (i) hiPSC-
CMs differentiated as previously described [25, 26] and
(ii) the same cells with an extra maturation step [27]
(please see material and methods section for details).
With the first hiPSC-CMs tested (without the extra mat-
uration step), cell viability was not affected by the injury
setup neither in mono-culture nor in co-culture with
hCPC conditions (Additional file 2: Figure S2). These re-
sults suggest that these cells were not metabolically ma-
ture enough, not reflecting the phenotype of adult CMs
found in the heart. Such results are in accordance with
the findings that point to a relevant role of CM matur-
ation stage on cell survival upon I/R injury. In fact, pri-
mary embryonic human CMs are resistant to hypoxia,
while primary adult human CMs are highly dependent
on an adequate oxygen supply, which might be related
with the different metabolic phenotypes between the dif-
ferent developmental stages [32, 33]. hiPSC-CMs with
an extra maturation step were therefore used in the fol-
lowing studies, since they better reflected the typical loss
of cell viability during AMI.
hiPSC-CM typical cardiac markers were not altered in
our assay conditions (ExpM at 3% O2, representing myo-
cardial physiological normoxia (Khan et al. [34])) when
compared to the cell’s maturation culture conditions
(Pluricyte® CM medium, 21% O2), presenting a high
percentage of cells positive for the cardiac-specific
proteins SIRPA (72.9% ± 5.2) and cTnT (92.6% ± 2.9)
(Additional file 3: Figure S3A) and the characteristic stri-
ated pattern of α-sarcomeric actinin (Additional file 3:
Figure S3B).
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The heterotypic model was subjected to I/R injury
(Fig. 1) and analyzed in terms of hCPC proliferation,
hiPSC-CM viability, secretion of key growth factors, angio-
genic potential, and hCPC whole proteome. Co-cultures
were compared with mono-cultures of the two cell types
and controls without injury.
hCPC proliferation is activated upon I/R in presence of
hiPSC-CM
hCPC proliferation was evaluated in control (CTL) and in-
jury conditions in mono- and co-culture with hiPSC-CMs.
hCPCs in co-culture with hiPSC-CMs showed a sig-
nificant higher fold increase at 16 h post reperfusion
when compared to the respective co-culture control (2.7
± 0.6 vs 1.8 ± 0.1, respectively, p = 0.0396) and when
compared with hCPCs in mono-culture in injury condi-
tion (2.7 ± 0.6 vs 1.4 ± 0.3, respectively, p = 0.0009)
(Fig. 2a, b).
To further confirm the differences observed in the
proliferation profile between hCPCs subjected to injury
in both mono- and co-culture conditions, hCPCs were
labeled with Ki-67, a marker specific for active prolifer-
ating cells. Although for all conditions tested the
percentage of Ki-67+ hCPCs was between 60 and 80%,
there was a significant decrease of Ki-67+ hCPCs at 1 h
post reperfusion in mono-culture in comparison with
co-culture conditions (59.3% ± 3.14 vs 68.8% ± 2.3, re-
spectively, p = 0.0163) (Fig. 2c, d), which might explain
the lower cell proliferation observed in this condition.
These findings suggest that injury diminishes hCPC pro-
liferation capacity, especially in the early reperfusion
period. Such effect is, however, prevented when the
co-culture model was used.
hCPC exert a paracrine protective effect on hiPSC-CM
upon I/R
The impact of I/R injury conditions in hiPSC-CM viabil-
ity was evaluated for mono- and co-culture conditions.
A decrease in viability was observed for hiPSC-CM upon
injury when compared to CTL, triggered after the first
hour of reperfusion (Fig. 3a). hCPCs exerted a paracrine





Fig. 2 Impact of I/R injury conditions on hCPC proliferation. a Fold increase in hCPC cell number. b Fold increase in hCPC cell number at 16 h
post reperfusion. c Quantification of Ki67+ hCPCs by immunostaining. d Representative culture imaging of Co CPC i and M CPC i labeled with
Ki67 at 1 h Post R. Black circles: mono-culture CTL (M CPC CTL); grey diamonds: co-culture CTL (Co CPC CTL); red squares: mono-culture hCPC
insult (M CPC i); green triangles: co-culture hCPC insult (Co CPC i). Post R: post reperfusion. *p < 0.05; **p < 0.01; *** p < 0.005. Fold increase was
calculated as the ratio between the cell number at the experimental time point assayed and cell number before injury
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condition, with a higher viability ratio across all reperfu-
sion time points assayed when compared with the
mono-culture condition, as confirmed by PrestoBlue®
Cell Viability Reagent results (Fig. 3a, b) and by cell
staining with live/dead cell dyes (Fig. 3c). At 16 h post
reperfusion, hiPSC-CM subjected to injury in co-culture
conditions presented significantly higher viability when
compared to hiPSC-CM in mono-culture (68.4% ± 3.0 vs
30.8% ± 17.9,respectively, p = 0.008) (Fig. 3b). When
comparing to respective controls, at 16 h post reperfu-
sion, hiPSC-CMs in mono-culture showed a significant
decrease of 62.8% in viability, while in co-culture,
hiPSC-CM viability dropped only by 21.9%.
Secretion of key growth factors is upregulated in I/R
To further access the paracrine effect observed in the
co-culture condition, the secretion of two key proteins
with documented cardiac regenerative properties was
quantified in our I/R system: chemokine ligand 6
(CXCL6 or GPC-2) and insulin-like growth factor 1
(IGF-1) [6, 35–37].
Regarding IGF-1, our data shows that both hCPCs and
hiPSC-CMs secrete IGF-1 either in mono- and co-
culture conditions (data not shown for hiPSC-CM
mono-cultures). IGF-1 is secreted and recognized by
both cell types [5, 37, 38]; therefore, it was not possible
to isolate and quantify how much IGF-1 each cell popu-
lation secreted in the co-culture condition, neither if
there was an uptake of IGF-1 by hiPSC-CM or hCPC.
We could not detect significant changes in IGF-1 secre-
tion upon injury neither in hCPC mono-cultures nor in
co-cultures with hiPSC-CMs (Fig. 4a).
CXCL6 seems to be selectively secreted by hCPC, as it
was not identified in either control or injury conditioned
medium of mono-cultures of hiPSC-CMs (data not
shown). However, in the co-culture condition, there is a
significant increase in CXCL6 cell-specific secretion rate
in both phases of injury, more pronounced during ische-
mia (Fig. 4b). In hCPC mono-culture conditions, we
A B
C
Fig. 3 Effect of I/R injury on hiPSC-CM viability. hiPSC-CM viability was assessed by PrestoBlue® assay (a, b) and by cell staining with FDA (live
cells, green) and PI (dead cells, red), scale bars 200 μm (c). Black circles: mono-culture hiPSC-CM CTL (M CM CTL); grey diamonds: co-culture
hiPSC-CM CTL (Co CM CTL); red squares: mono-culture hiPSC-CM insult (M CM i); green triangles: co-culture hiPSC-CM insult (Co CM i). Post R:
post reperfusion. * p < 0.05; ** p < 0.01; *** p < 0.005
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observed some alterations in the CXCL6 cell-specific se-
cretion rates during injury, but such rates do not differ
between control and injury (Fig. 4b).
CXCL6 is described as being an angiogenic chemokine
secreted by CPCs [21]. In order to access if the I/R
conditioned medium has a pro-angiogenic paracrine
profile, the in vitro tube formation assay was performed.
HUVECs were incubated with conditioned media from
co-cultures and mono-cultures of hCPCs upon ischemic
injury. As shown in Fig. 5, the angiogenic potential of
the conditioned medium from the co-culture condition
post ischemia is higher when comparing to the mono-
culture medium, represented by a significant increase in
total segment length and total branching length as well
as by a higher number of nodes (Fig. 5a).
Proteomic analysis of hCPCs reveals enrichment in key
hallmark pathways and functions upon injury
To further understand the regenerative response of
hCPCs to the I/R injury, whole proteome analysis of
hCPCs was performed in all culture conditions. More
than 3800 proteins were identified in all samples (Fig. 6).
Biological canonical pathway and functions (terms) en-
richment analysis was performed using IPA software
(full list of scores of canonical pathways and functions
analysis in Additional file 4). Our analysis was focused
on terms with relevant described roles in AMI, associ-
ated with the following categories: cell proliferation,
cytoskeleton organization, maintenance of cell viability,
cell death, oxidative stress, paracrine signaling, regener-
ation, stress response, and metabolism.
Proteins exclusively identified in hCPCs subjected to I/
R injury in mono- (M CPC i) and co-culture (Co CPC i)
(n = 690) were analyzed. Within this subset, from the 10
top terms with the highest number of proteins, 7 were
associated with cell death and viability (Fig. 6), suggest-
ing that the I/R injury setup elicited an hCPC physio-
logical response involving activation of mechanisms of
cell survival.
Approximately 9% of the identified proteins (n = 354)
were exclusively identified in hCPCs subjected to injury in
co-culture conditions (Co CPC i). Within this subset, there
was a high enrichment in proteins associated with cell pro-
liferation (n = 83), cell viability (n = 32), organization of
cytoplasm (n = 27), organization of cytoskeleton (n = 22),
and metabolism of protein (n = 20), all included in the 10
top terms (Fig. 6). By exploring in more detail this sub-
group of proteins (Additional file 5: Figure S4), we can
highlight the identification of APOD and APOH, proteins
involved in CM viability and opsonization [39], proteins
associated with CXCR4 signaling (RHOB, PIK3R1, GNAQ,
PRKCA, RPS6KB2), proteins associated with IGF-1 signal-
ing (JAK1, PIK3R1, RPS6KB2, SFN, RASA1, IGFBP2), and
SERPINB3, a protease inhibitor activated by hypoxia [40]
with described roles in protection from oxidative damage
[41], cell proliferation [42], IL-6 signaling, and unfolded
protein response [43].
Moreover, several other pathways and functions relevant
in I/R response were enriched in Co CPC i proteome when
compared to control (Co CPC CTL) (Additional file 6:
Table S1) and M CPC i (Additional file 7: Table S2), in-
cluding cell proliferation via EGF-mediated pathways,
pathways associated with actin filaments, with reactive
oxygen species (ROS) metabolism, corticotropin-releasing
hormone signaling (described has playing a major role in
cell adaptation under stressful conditions [44]), and
A B
Fig. 4 Specific rates of CXCL6 and IGF-1 secretion during ischemia and reperfusion. a qIGF-1 measured in conditioned media of mono-culture
hCPC CTL (M CPC CTL); mono-culture hCPC insult (M CPC i) and co-culture hCPC:hiPSC-CM insult (Co i). b qCXCL6 measured in conditioned
media of mono-culture hCPC CTL (M CPC CTL); mono-culture hCPC insult (M CPC i) and co-culture hCPC:hiPSC-CM insult (Co i). Specific growth
factor secretion rates were normalized to the values before insult (dashed line). * p < 0.05; ** p < 0.01; *** p < 0.005; ¤ p < 0.05; ¤¤ p < 0.01; ¤¤¤ p <
0.005; ¤¤¤¤ p < 0.0001 vs before insult
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glycolysis. Paracrine signaling terms more enriched in
Co CPC i proteome included IGF-1, HGF, VEGF, Oncos-
tatin M, Neuregulin, Netrin, PDGF, IL-1, IL-2, IL-3, and
IL-6 signaling pathways (Additional file 6: Table S1 and
Additional file 7: Table S2), all with documented roles in
myocardial I/R [45–48].
Following this first comparative analysis, a more ex-
haustive proteomics characterization of hCPCs in the
co-culture condition was carried out. Term enrichment
was compared between different time points, namely in
the control situations (Co CPC CTL), immediately post
ischemia period (Co CPC Post I), 1 h post reperfusion
(Co CPC 1 h Post R), and 16 h post reperfusion (Co
CPC 16 h Post R) (Additional file 8)
By analyzing the different time points, terms related
with cell proliferation via EGF (EGF, cholecystokinin/
gastrin-mediated and ERK5 signaling) were found as
having an increasing representation along injury
(Additional file 8, Category 1). FLT3 signaling was also
identified as more enriched at 16 h post reperfusion,
while cytokinesis (Additional file 8, Category 1) and
IGF-1 signaling, also involved in cell proliferation
activation [49] (Additional file 8, Category 5), were
found as more enriched post ischemia. Regarding terms
A
B
Fig. 5 Angiogenic functional evaluation of I/R conditioned medium. Ischemic mimetic solution (IMS), endothelial cell growth medium 2 (ECGM2),
and conditioned media of hCPC mono-culture post ischemia (M CPC i Post I) and of co-culture post ischemia (Co i Post I) conditions were tested
for angiogenic potential by HUVECS tube formation assay. a Total segment length, total branching length, and number of nodes are represented.
¤¤ p < 0.01; ¤¤¤ p < 0.005; ¤¤¤¤ p < 0.0001 vs IMS. b Representative original images (left) and quantification by angiogenesis analyzer are shown. In
the right image, there is an indication of master junctions (pink dots), master segments (yellow), meshes (light blue), branches (green), and
isolated segments (blue). Scale bars 200 μm
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associated with cytoskeleton organization (Additional file
8, Category 2), cell invasion, extension, and CCR3 sig-
naling (involved in eosinophils recruitment to inflamma-
tion sites [50]) were enriched after the ischemic period,
while terms associated with cell movement were
enriched at 1 h post reperfusion, suggesting an activation
of hCPC migration and homing to injury in these early
injury time points. Importantly, although several terms
related with cell death and survival were found as less
enriched in hCPCs upon ischemia, the same returned to
their control levels during the reperfusion period
(Additional file 8, Category 3).
It is worth to mention that the cell cycle regulation
pathways (Additional file 8, Category 1) and DNA repair
mechanisms, including the BER pathway (Additional file
8, Category 3) representation, decreased on early injury
time points and recovered to values closer to control at
16 h post reperfusion. Regarding oxidative stress, terms
related with degradation and metabolism of H2O2 and
HIF-1a signaling were found as more enriched in hCPCs
post ischemia (Additional file 8, Category 4).
IGF-1 and GM-CSF signaling was also more represented
upon ischemia (Additional file 8, Category 5), while other
pathways associated with cytokine/growth factor paracrine
signaling and cardiac regeneration were found as more
enriched in hCPCs after 16 h of reperfusion, including VEGF,
Neuregulin, Oncostatin M, Jak/Stat, PDGF, IL-2, IL-3, IL-6,
IL-15, and IL-22 signaling (Additional file 8, Category 5).
Fig. 6 hCPC whole proteome analysis. Venn diagram illustrates the overlap between proteins identified in hCPCs in mono-culture control (M CPC
CTL), co-culture control (Co CPC CTL), mono-culture insult (M CPC i), and co-culture insult (Co CPC i) conditions. Top 10 canonical pathways and
functions with −log(p value) ≥ 1.3 and the highest number of identified proteins are highlighted for the subsets of proteins exclusively identified
in hCPCs subjected to I/R injury in both mono- and co-culture conditions (CPC i, red) and for the subset of proteins exclusively identified in Co
CPC i proteome (green)
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Stress response-associated functions such as hypersen-
sitive reaction, endoplasmic reticulum stress (ERS),
unfolded protein response (UPR), and cardiac
β-adrenergic signaling were more enriched upon ische-
mia (Additional file 8, Category 6), while acute phase
response signaling and stress response of cell representa-
tion was higher at 1 h post reperfusion. Importantly, car-
diac regeneration associated functions such as cell
differentiation, vasculogenesis, and angiogenesis were
also found as more enriched after 16 h of reperfusion
(Additional file 8, Category 6). Cysteine biosynthesis and
glutathione-mediated detoxification terms, both import-
ant for protection from oxidative stress [51], were found
as more enriched post ischemia (Additional file 8,
Category 7). Glycolysis and oxygen consumption-related
pathways was also found to be more represented upon
ischemia (Additional file 8, Category 7), which might
point to a compensatory mechanism to lack of oxygen
availability during this phase of injury.
Discussion
In this study, we developed an in vitro human cellular
model of myocardial I/R injury with hCPCs and
hiPSC-CMs that enabled us to further decipher the ac-
tion mechanisms of hCPCs upon injury. The co-culture
model developed recapitulates important hallmarks of I/
R injury, namely CM death, CPC proliferation activation
upon insult, and the protective role of CPCs on CMs.
New players on hCPC regeneration response upon I/R
including activation of pathways related with cell prolif-
eration, cytoskeleton organization, maintenance of cell
integrity, stress response, paracrine signaling, cardiac re-
generation, and metabolism were identified based on
proteome hCPC data (Fig. 7). We also showed, for the
first time, an increase in the CXCL6 secretion rate by
hCPCs in an I/R setting.
During the ischemic phase of injury, cells were cul-
tured in conditions mimicking the myocardial patho-
physiological state of ischemia including lack of oxygen
availability, nutrient deficiency, acidosis, lactate accumu-
lation, and hyperosmosis [28]. hCPC proteomic analysis
results point to a downregulation of cell cycle regulation
pathways, DNA repair mechanisms, and cell repair
mechanisms during the ischemic phase of injury (Fig. 7a).
In fact, downregulation of cell cycle checkpoint control
and DNA repair processes has been reported as a
process involved in activation of several types of quies-
cent adult stem cells [52]. Proteome analysis also indi-
cates an activation of endoplasmic reticulum stress
pathways, such as ERS and UPR, which have been previ-
ously associated with cellular adaptation to glucose
deprivation and hypoxic stimuli [53]. Proteins associated
with glycolysis and consumption of oxygen were also
enriched in this time point, which might point to an
adaptive response of hCPCs to the lack of O2, via an in-
crease in the expression of protein machinery associated
with energy production.
The ability of CPCs to differentiate into de novo CMs
upon AMI is still under active discussion, with different
authors defending contrary results [11, 12, 54]. In our
model, hCPCs did not label for Nkx2.5, an early marker
of cardiac differentiation (results not shown) neither in
CTL nor in injury conditions, although an enrichment
in proteins related with cell differentiation was found in
hCPCs upon the ischemic phase of injury.
Although such controversy still exists regarding cardiac
differentiation potential of CPCs upon injury, there is a
general consensus in the field that CPCs exert a protective
effect on hCMs under stress mainly due to paracrine mech-
anisms [37, 55], supported by extensive preclinical and clin-
ical data indicating that transplanted CPCs do not survive
neither engraft in the myocardium while physiological im-
provement is still registered [4]. In order to further under-
stand the paracrine crosstalk between hCPCs and
hiPSC-CMs in our model, we quantified the secretion of
two key proteins: CXCL6 and IGF-1, both with docu-
mented cardiac regenerative properties. CXCL6 is an angio-
genic chemokine shown to improve heart function in mice
[21, 35] and identified as upregulated during mesenteric
(intestinal) I/R injury [56]. This chemokine was also re-
cently identified in the secretome of hCPCs, where addition
of an anti-CXCL6 antibody inhibited the migration and an-
giogenic properties of CPC conditioned medium, proving
the importance of this chemokine in key paracrine regen-
erative potential features of these cells [21]. We show for
the first time an increase in the hCPC CXCL6 secretion-
specific rate in a myocardial I/R injury setting, which was
more pronounced during ischemia, but still significant after
16 h of reperfusion (Fig. 7a, c). These results support pre-
vious findings that show that this chemokine is upregu-
lated in ischemic conditions via HIF-1α signaling [57].
Cardiac stem cells have been shown to home and mi-
grate to the site of injury, a process activated by HIF-1α
transcription factor and SDF-1 chemokine in response
to ischemia [58]. Although CXCL6 was not identified
by proteome analysis, an enrichment in proteins related
to HIF-1α signaling, and CCR3 signaling, a pathway im-
portant for cell homing to inflammation and injury sites
[50], was also found in hCPCs upon ischemia (Fig. 7a).
Moreover, we were able to identify proteins associated
with CXCR4 signaling, a pathway activated by SDF-1
with documented roles in cell motility and chemotactic
response [59]. Altogether, our data and previous reports
regarding CPC secretome, namely CXCL6 function,
point to an effect of this chemokine in hCPC migration
and angiogenesis. In fact, we also demonstrate pro-an-
giogenic properties of conditioned medium from the
ischemic phase of injury.
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IGF-1 is one of the key proteins shown to be upregu-
lated upon injury or stress by CPCs [38, 60] and CMs
[46, 49] and has also been shown to have a role in the
activation of hCPC regenerative potential [37, 55] and
proliferation [46, 49] in vitro and in vivo. Although no
significant increase in IGF-1 secretion was detected by
ELISA, we registered an enrichment in IGF-signaling
associated proteins in hCPC proteome upon ischemia
and reperfusion time points (Fig. 7a, c). Several other
proteins associated with other cytokine/growth factor
paracrine signaling pathways were also found to be




Fig. 7 Schematic representation of proposed mechanisms involved in hCPC response to the I/R injury model, during a ischemia, b early (1 h post
reperfusion), and c late (16 h post reperfusion) reperfusion phases of I/R injury
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including VEGF, IL-2, IL-3, IL-15, and GM-CSF signaling,
all with documented paracrine roles acting in CM physi-
ology during I/R injury [45, 61, 62].
hCPC proteome upon ischemia was also enriched in
terms related with ROS metabolism, cysteine synthesis,
glutamate metabolism, and glutathione-mediated de-
toxification (Fig. 7b). L-cysteine is one of the main pre-
cursors for glutathione, a molecule that protects cells
from oxidative stress [51]. In fact, glutaminolysis, a
pathway that leads to the production of glutathione via
L-cysteine and glutamate, was found as a key energy
source for proliferating mouse CPCs [63]. ROS forma-
tion and oxidative stress has been described as caused
by the sudden oxygen elevation in the early reperfusion
phase of injury [2], rather than during ischemia. How-
ever, during the preparation of the samples for prote-
omic analysis upon ischemia, hCPCs were briefly
subjected to atmospheric oxygen concentrations, which
could induce such oxidative stress responses. Together,
these data point to a mechanistic response of hCPCs to
ischemia phase of injury focused on a downregulation
of cell cycle checkpoint and DNA repair processes in
favor of an enrichment in proteins associated with
stress coping mechanisms, induction of cell homing
and motility, and activation of pathways associated with
paracrine communication including CXCL6 secretion
(Fig. 7a). Such paracrine signaling activation is de-
scribed as having a beneficial effect on CM protection.
hCPC paracrine protection on hiPSC-CM was recapitu-
lated in our model. Viability of hiPSC-CMs was mainly
affected in the early reperfusion phase of the injury,
which is consistent with the described in vivo patho-
physiology of CM death during I/R, where the first
minutes of reperfusion are also the main trigger for CM
death and tissue damage due to the oxidative stress,
calcium overload, mitochondrial permeability pore
opening, and hypercontracture [2].
Several authors have reported an increase in the
number of resident CPC upon AMI in animal model
[38, 54] hearts. Stastna et al., in 2010, also showed that
connective tissue growth factor, a pro-fibrosis factor re-
leased by CMs upon AMI, induces rat CPC prolifera-
tion in vitro and atrial natriuretic peptide, a vasodilator
molecule also secreted by CMs, had an opposite effect,
decreasing rat CPC proliferation [64]. These results
suggest that CPC proliferation is regulated upon injury
by paracrine factors secreted by CMs. In fact, in our
co-culture I/R injury model, we were able to observe a
significant increase in hCPC proliferation upon reperfu-
sion (Fig. 7b, c). Our hCPC whole proteome results also
showed higher enrichment of pathways related with cell
proliferation via EGF signaling after reperfusion, which
points to EGF as one of the key actuator signals in CPC
proliferation activation upon AMI (Fig. 7b, c). In fact,
EGF has been reported as having a positive effect on
cardiosphere-derived hCPCs proliferation and migra-
tion [65], as being one of the main factors secreted in
mice CPC conditioned medium [55], as upregulated in
mice CPCs upon injury [38], and EGF receptor has also
been identified in a hCPC receptome characterization
study by our group [19]. Other signaling pathways de-
scribed to be related with cell proliferation were also
found to be more enriched at 16 h post reperfusion,
such as FLT3 signaling (Fig. 7c), a pathway described as
important for proliferation in hematopoietic progenitor
cells [66], cytokinesis, and IGF-1 pathway.
Collectively, our data suggests an hCPC response to
early reperfusion through activation of paracrine signaling
mechanisms (including acute phase response signaling),
cell proliferation, glutathione-mediated ROS detoxifica-
tion, and cell movement, while still inhibiting cell cycle re-
pair mechanisms (Fig. 7b). Later in reperfusion, hCPC
proteome also demonstrated an enrichment in several
pathways associated with cytokine/growth factor paracrine
signaling, all with documented paracrine roles acting in
CM physiology during I/R injury, including CXCL6 secre-
tion, a recovery of cell cycle repair mechanisms, and
activation of angiogenesis and vasculogenesis-related
pathways (Fig. 7c). These results are in line with the
concept that hCPC regenerative capacity is mainly cen-
tered on their paracrine potential, being CXCL6 one of its
critical players.
Our data support the importance of a paracrine cross-
talk between CPCs and CMs during AMI, and the idea
that heterotypic cell models better recapitulate in vivo
features of I/R when compared to monotypic models.
Conclusions
The I/R injury model developed recapitulates important
hallmarks of AMI. The use of robust advanced analytical
technologies such as LC-MS/MS whole cell proteome
analysis, combined with more classical and targeted
methodologies (ELISA growth factor quantification, via-
bility assays) and functional assays (tube formation
assay), enabled us to further understand the response of
hCPC to I/R injury, shedding new insights on the pos-
sible mechanisms involved. We show, for the first time,
an increase in CXCL6 secretion by hCPCs in a myocar-
dial I/R setting, reinforcing the described role of CXCL6
in hCPC regenerative and pro-angiogenic potential and
suggesting the importance of this chemokine in the
paracrine-mediated protective effect of CPCs in the
myocardium upon AMI. The results reported herein
strengthen the importance of studying physiological pro-
cesses using more complex human co-culture in vitro
models leading to a better recapitulation of the in vivo
paracrine signaling and a more relevant model for future
applications such as drug discovery.
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This work provides new insights and raises new ques-
tions related with hCPC biology in acute myocardial
infarction. We believe that our model provides an im-
portant tool towards a better understanding of hCPC
action mechanisms upon AMI, which will enable the de-
velopment of novel therapies focused on activation,
recruitment, and improvement of the endogenous heart
regeneration capacity.
Additional files
Additional file 1: Figure S1. Phenotypic characterization of hCPCs.
hCPCs were characterized using specific cell markers by flow cytometry
(A) and immunostaining (B). Scale bars: 50 μm. Error bars represent SD of
n = 3 (unpaired t test). (PPTX 662 kb)
Additional file 2: Figure S2. Effect of I/R injury on hiPSCs-hCMs without
maturation step. Viability of hiPSC-CMs after 15 days of differentiation
(without maturation step) was assessed by PrestoBlue® assay (A) and by
cell staining with FDA (live cells, green) and PI (dead cells, red), scale bars
200 μm (B). Black circles: mono-culture hiPSC-CMs CTL (M CM CTL); Red
squares: mono-culture hiPSC-CMs insult (M CM i); Green triangles: co-
culture hiPSC-CM insult (Co CM i). Post R: Post Reperfusion. (PPTX 1304
kb)
Additional file 3: Figure S3. Phenotypic characterization of hiPSC-CMs.
hiPSC-CMs were characterized using specific cell markers by flow
cytometry (A) and immunostaining (B). hiPSC-CMs retain their
cardiomyocyte markers expression after 2 days in assay conditions
(expansion medium at 3% O2: light gray bars) comparing to the hiPSC-
CM maturation culture conditions (Pluricyte® CM medium at 21% O2:
dark gray bars). Scale bars: 50 μm. Error bars represent SD of n = 3
(unpaired t test). (PPTX 791 kb)
Additional file 4: Top IPA Canonical Pathways, Diseases and Bio
Functions identified. (XLSX 156 kb)
Additional file 5: Figure S4. Proteins identified in hCPCs. Venn diagram
illustrates the overlap between proteins identified in hCPCs in: mono-culture
control (M CPC CTL); co-culture control (Co CPC CTL); mono-culture insult
(M CPC i), and co-culture insult (Co CPC i) conditions. Proteins related with
cell proliferation, cytoskeleton organization, maintenance of cell integrity, cell
death, paracrine signaling, regeneration, stress response, and metabolism
are highlighted for the subset of proteins identified exclusively in Co CPC i
proteome. (PPTX 312 kb)
Additional file 6: Table S1. Canonical pathways and functions enriched
in Co CPC I vs Co CPC CTL. –log (p value) ≤ 1.3 were considered as non-
significant (n.s.) (less than 95% confidence). Pathway/ function terms were
only selected for analysis when –log (p value) ratio between the two
conditions ≥ 1.2. (DOCX 26 kb)
Additional file 7: Table S2. Canonical pathways and functions enriched
in co CPC I vs mono CPC i. –log (p value) ≤ 1.3 were considered as non-
significant (n.s.) (less than 95% confidence). Pathway/ function terms were
only selected for analysis when –log (p value) ratio between the two
conditions ≥ 1.2 (DOCX 27 kb)
Additional file 8: Canonical pathways and functions differentially
enriched in Co CPC CTL and Co CPC throughout injury. (DOCX 37 kb)
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